Bioinformatic detection of copy number variation in <i>HNF4A</i> causing maturity onset diabetes of the young

To the Editor: Maturity onset diabetes of the young (MODY)1, 2 is currently under-recognized clinically,3 and may also be under-recognized by molecular genetic analysis.1 Genetic testing for MODY is presently accomplished primarily using next generation sequencing (NGS) techniques.1, 2, 4 However, these techniques are historically unable to detect copy number variations (CNVs), defined as large-scale deletions or duplications in genomic DNA. We report here on a large-scale heterozygous CNV in HNF4A causing MODY in an individual who initially tested negative for mutations by DNA sequencing alone. The proband carrying this mutation was a Caucasian female, diagnosed with diabetes at age 16. She has a normal body mass index with negative diabetes-associated autoantibodies and a significant family history of diabetes. She was managed effectively with a sulphonylurea for several years, with improvement in HbA1c from 7.5% to 5.6% compared to multiple daily injections of insulin. Sulphonylurea therapy eventually became ineffective and insulin was re-initiated. The proband provided informed consent and DNA was obtained from whole blood in 2005 under a protocol approved by the University of Western Ontario Ethics Review Board (#07920E). LipidSeq,5 a targeted NGS and bioinformatics platform, was used to assess for pathologic mutations in known MODY-associated genes, and none were detected. Her original NGS output data was recently re-analyzed 13 years after the original testing was completed using the VS-CNV caller function in VarSeq v1.4.3 (Golden Helix, Bozeman, Montana), a technique that takes advantage of depth-of-coverage (DOC) information provided from raw NGS data to predict the presence of CNVs. A whole-gene deletion of HNF4A (MODY1) was detected (Figure 1B). The CNV average ratio for this deletion was 0.531123 with a Z-score of −6.6691 (significance threshold −5) for the targeted NGS data and an average ratio of 0.577031 with a Z-score of −2.94078 (significance threshold −2) and a P-value of <1 × 10−30 for confirmatory whole exome sequencing (WES). This deletion has not been previously reported and would be expected to be causal for MODY. The detected CNV was further confirmed using CytoScan array (Affymetrix Santa Clara, California), a clinically validated tool to detect CNVs, which similarly demonstrated a large-scale deletion spanning this region (Figure 1A). The breakpoint was established using polymerase chain reaction (PCR)-based probe analysis and Sanger sequencing using primers designed to target either side of the suspected breakpoint. This confirmed the presence of a heterozygous 242 258 bp deletion spanning chr20:42871409-43 113 666 (Figures 1C-E). A diagnosis of MODY1, seen here, leads to a mild-moderately severe, progressive form of diabetes.3 As demonstrated by the proband, MODY1 may be optimally treated with low-dose oral sulfonylurea therapy for many years, although insulin therapy may eventually be required.4 Our findings suggest that incorporating CNV analysis routinely during genetic testing for MODY may improve diagnostic yield and may also help establish the true prevalence of CNVs as a cause of MODY. A.J.B. (guarantor) is supported through the Dr. Fernand Labrie Fellowship Research Grant from the Canadian Society for Endocrinology and Metabolism. R.A.H. is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Research Chair in Human Genetics, and the Martha G. Blackburn Chair in Cardiovascular Research. R.A.H. has also received operating grants from the Canadian Institutes of Health Research (Foundation award) and the Heart and Stroke Foundation of Ontario (G-18-0022147). There is no associated shared data.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.